Sigachi Industries Reports Rs 121.27 Crore Revenue in Q1 FY27; Dahej Expansion Shifted

Sigachi Industries posted Rs 121.27 crore in revenue for the first quarter of fiscal year 2027 (Q1 FY27). The company also updated its Dahej-2 expansion timeline, now targeting completion by Q2 FY28.

Reader Takeaway: Revenue steady amid expansion delay; watch capex funding and insurance payout.

What just happened

Sigachi Industries announced its financial results for Q1 FY27, recording total operating income of Rs 121.27 crore. The company's core Microcrystalline Cellulose (MCC) segment contributed Rs 82.74 crore, while the O&M and API segments added Rs 13.06 crore and Rs 21.68 crore, respectively. EBITDA stood at Rs 16.5 crore, with a margin of 13.6%, and Profit After Tax (PAT) was Rs 8.14 crore, reflecting a 6.76% margin.

Why this matters

Despite a Rs 16.5 crore EBITDA, the margins were impacted by ongoing expansion costs and a slight delay in a key project. The company's ability to maintain revenue and improve segment contributions, particularly in the higher-margin API business, is crucial for investor confidence. The updated expansion timeline and clarity on capex funding will be key factors influencing future growth prospects.

The backstory

Sigachi Industries is a global leader in microcrystalline cellulose (MCC) and other excipients. The company has been focused on expanding its manufacturing capabilities to meet growing demand and diversify its product portfolio, including its API business. Past quarters have seen steady performance, with a focus on operational efficiency and market penetration.

What changes now

The Dahej-2 expansion, a significant capacity increase, is now slated for Q2 FY28, pushing back the expected volume and revenue contributions. Management is planning substantial capital expenditure (capex) of over Rs 100 crore for FY27 and Rs 150-200 crore for FY28, the funding for which is still under consideration, with options including debt and potential equity issuance.

Risks to watch

Key risks include the delay in the Dahej-2 expansion, uncertainty surrounding the funding for significant capex plans, and the timing of a potential Rs 16.5 crore payout from a business continuity insurance claim, expected by September. High current receivable days (93-94 days) also present a working capital challenge.

Peer comparison

(No specific peer comparison data was provided in the filing. Generally, companies in the excipient and API space focus on capacity expansion, R&D, and quality certifications to maintain market share and margins.)

Context metrics (time-bound)

• Q1 FY27 Revenue: Rs 121.27 crore
• MCC Realization: Rs 241.36 per kg (up from Rs 216/kg in Q4 FY26)
• Capacity Utilization: 76.8% (average)
• Dahej-2 Expansion Target: Q2 FY28 (delayed)
• FY27 Revenue Guidance: Rs 650 - 675 crore
• FY27 EBITDA Margin Target: 18%
• FY27 Capex: Over Rs 100 crore
• FY28 Capex: Rs 150-200 crore
• Expected Insurance Payout: Approx. Rs 16.5 crore (by September)
• Receivables: 93-94 days

What to track next

Investors will be closely watching the finalization of capex funding strategies, the progress of the Dahej-2 expansion towards its new deadline, and the successful realization of the insurance claim. Improvement in working capital management and consistent performance in the API segment will also be critical indicators.